Research into facioscapulohumeral muscular dystrophy has accelerated sharply in recent years, with multiple therapeutic strategies now in clinical or late preclinical development and new biomarkers emerging that could reshape how trials are designed and monitored. FSHD, one of the most common inherited muscular dystrophies, has long frustrated researchers because its underlying genetic mechanism is unusually complex. But a clearer picture of how the disease works at the molecular level has opened the door to targeted treatments, and several are now being tested in people for the first time.
The DUX4 Problem at the Heart of FSHD
Nearly all current therapeutic strategies for FSHD converge on a single target: a gene called DUX4. In healthy adults, DUX4 is silenced in most tissues. In FSHD, a combination of genetic changes causes DUX4 to become inappropriately active in skeletal muscle cells, where it sets off a cascade of damage. The disease comes in two genetic forms. In FSHD1, the more common type, the D4Z4 repeat array on chromosome 4 is abnormally short, contracted from a normal range of 8 to 100 repeating units down to just 1 to 10 units. In the rarer FSHD2, the repeat array is somewhat shortened (8 to 20 units) and is combined with mutations in a chromatin-modifying gene called SMCHD1.
1Human Molecular Genetics. Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2Both forms lead to the same result: the chromatin packaging around D4Z4 loosens, and DUX4 protein gets made in muscle cells where it does not belong. Recent isogenic cell line experiments have shown that SMCHD1 mutations do not simply add to the effect of D4Z4 contraction but act through a distinct mechanism, stabilizing DUX4 target gene activation that would otherwise flicker on and off unpredictably.
2Cell. D4Z4 contraction and SMCHD1 mutation differentially affect the DUX4 gene network and heterochromatin in facioscapulohumeral dystrophyOnce DUX4 is active, it triggers a range of harmful molecular events. It suppresses the myogenic program that muscle cells need to grow and repair, leaving them more vulnerable to oxidative stress. It also drives the accumulation of double-stranded RNA in cells, which activates an antiviral-like alarm system that leads to cell death.
3PLoS Genetics. DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophyResearch has identified at least two distinct cell-death pathways triggered by DUX4. One operates through the conventional apoptosis machinery. Another, discovered more recently, works through a protein called RIPK3 and proceeds independently of the standard apoptotic enzymes. In mouse models, blocking this RIPK3-mediated pathway improved muscle mass and reduced activation of DUX4’s downstream gene network.
4PubMed Central. RIPK3-mediated cell death is involved in DUX4-mediated toxicity in facioscapulohumeral dystrophyBiopsies from FSHD muscle also reveal a strong immune and inflammatory signature alongside the DUX4-driven gene expression changes, with genes linked to immune response, immunoglobulins, and extracellular matrix remodeling contributing heavily to the overall molecular differences between FSHD and healthy muscle.
5Human Molecular Genetics. Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsiesA xenograft model using human FSHD muscle transplanted into mice found that FSHD tissue preferentially attracted macrophages and B cells and activated early complement pathways, suggesting that inflammation is not just a bystander but an active contributor to muscle damage.
6bioRxiv. A human immune/muscle xenograft model of FSHD muscle pathologyRNA-Targeted Therapies Move Into the Clinic
The most advanced therapeutic approach in the FSHD pipeline aims to intercept DUX4 at the RNA level, preventing the harmful protein from being made in the first place. The leading candidate is delpacibart braxlosiran (del-brax, also called AOC 1020), developed by Avidity Biosciences. Del-brax is an antibody-oligonucleotide conjugate: a small interfering RNA designed to degrade DUX4 messenger RNA, attached to an antibody that binds a receptor on muscle cells, allowing the drug to enter skeletal muscle specifically.
7PubMed Central. Development of a DUX4-targeting antibody oligonucleotide conjugate as a therapy for FSHDDel-brax is currently the subject of a global confirmatory phase 3 clinical trial, and the FDA’s accelerated approval pathway has been confirmed as open for this compound. If successful, this would represent the first approved treatment for FSHD. The approach is notable because earlier efforts to deliver RNA-based therapeutics to muscle were hampered by poor tissue uptake. By hitching the therapeutic RNA to an antibody that homes in on a muscle-cell surface receptor, the drug achieves more efficient delivery than naked oligonucleotides could manage on their own.
Other RNA-targeting strategies are at earlier stages. Antisense oligonucleotides that block the polyadenylation signal at the end of the DUX4 transcript have shown promise in cell models and in mice. Without that signal, the DUX4 messenger RNA cannot be properly processed and stabilized, so DUX4 protein production drops. Several research groups have demonstrated that targeting this specific region of the transcript can reduce DUX4 and its downstream targets without obvious off-target effects.
8PubMed Central. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse modelMorpholino-based antisense molecules targeting the same polyadenylation signal have likewise knocked down DUX4 target genes in FSHD cell cultures with minimal toxicity, and transcriptomic analysis showed broad suppression of the DUX4 gene network without major unintended effects on other pathways.
9Molecular Therapy. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy TherapeuticsLessons from the Losmapimod Trial
Before the RNA-based approaches reached clinical testing, the most closely watched FSHD drug candidate was losmapimod, a p38 MAPK inhibitor. The rationale was straightforward: p38 signaling drives DUX4 expression during early muscle cell differentiation, and lab studies confirmed that losmapimod could suppress DUX4 and its targets during that early window.
10Scientific Reports. Temporal variation in p38-mediated regulation of DUX4 in facioscapulohumeral muscular dystrophyThe phase 2b ReDUX4 trial, however, did not show a statistically significant difference between losmapimod and placebo on its primary endpoint of DUX4-driven gene expression, with the treatment effect not reaching significance.
11PubMed. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trialThe result was a disappointment for the FSHD community, though it offered important lessons. One takeaway is that DUX4 expression in mature muscle tissue is extremely sparse and variable, making it hard to detect changes with conventional biopsy-based readouts. Another is that blocking one upstream pathway may not be sufficient if multiple converging signals sustain DUX4 activity. The trial also underscored the urgent need for better biomarkers that can detect therapeutic effects more sensitively than muscle biopsies currently allow.
Gene Editing and Epigenetic Silencing
Because FSHD fundamentally arises from a failure of gene silencing, several groups are exploring whether the silencing can be restored using gene-editing tools. Rather than cutting the DNA, most of these approaches use a deactivated version of the Cas9 protein (dCas9) fused to molecules that suppress gene activity. When directed to the DUX4 promoter or first exon, this epigenetic CRISPR system reduced DUX4 messenger RNA to roughly 30 to 50 percent of its unedited levels in FSHD patient cells, with a corresponding drop in DUX4 target gene expression.
12Molecular Therapy. Muscle-Specific Epigenetic CRISPR Inhibition Represses DUX4 in Cellular and Animal Models of Facioscapulohumeral Muscular DystrophyA complementary strategy uses dCas9 fused to DNA methylation enzymes to add methyl marks back to the D4Z4 repeats, essentially re-locking the chromatin that has come undone. This “hit-and-run” approach has suppressed endogenous DUX4 in patient-derived stem cells, and the silencing persisted even after the editing machinery was removed, suggesting the epigenetic correction can be self-sustaining.
13bioRxiv. Hit-and-run silencing of endogenous DUX4 by targeting DNA hypomethylation on D4Z4 repeats in facioscapulohumeral muscular dystrophyThese approaches are still preclinical, and delivering them to muscle tissue throughout the body remains a significant challenge. Viral vector-based gene therapy is also being explored: AAV-delivered microRNAs designed to degrade DUX4 transcripts have been tested in animal models, with recent work focusing on improving vector safety profiles before efficacy testing in vivo.
14Molecular Therapy. Improved Vector Design and Toxicological Assessment of DUX4-Targeted MicroRNAs for Facioscapulohumeral Muscular Dystrophy Gene TherapyA separate gene therapy strategy sidesteps DUX4 entirely, instead delivering follistatin, a natural inhibitor of the muscle-wasting protein myostatin. In a DUX4-expressing mouse model, AAV-delivered follistatin significantly increased muscle mass and strength even while DUX4 was still being produced, suggesting it could work as a supportive treatment alongside DUX4-targeting therapies.
15PubMed Central. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHDBetter Biomarkers for Tracking the Disease
One of the persistent frustrations in FSHD clinical research is that the disease progresses slowly and unevenly. Muscles can go years with little change and then deteriorate rapidly, and the pattern varies enormously between patients and even between muscles in the same person. This makes it hard to design trials that can detect a treatment effect in a reasonable timeframe. Researchers have been investing heavily in biomarkers that can capture disease activity more sensitively.
Quantitative muscle MRI has emerged as one of the most promising tools. By measuring the fraction of muscle tissue replaced by fat, researchers can track degeneration with greater precision than clinical strength testing alone. A one-year longitudinal study found that muscles with intermediate levels of fat replacement progressed the most, while muscles that were still mostly healthy or already severely affected changed little. Fat fractions above about 20 percent were associated with significant weakness, suggesting this threshold could serve as a meaningful target for trials aiming to prevent functional decline.
16PubMed Central. Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophyA five-year follow-up study confirmed that the MRI-measured fat fraction increased over time and correlated with worsening clinical scores, further establishing quantitative MRI as a viable readout for trials.
17PubMed Central. Five‐year follow‐up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophyMore recently, multiparametric MRI protocols that measure both fat replacement and muscle water content (a marker of inflammation and edema) have added another dimension. Muscles with elevated water content at baseline were the ones most likely to accumulate fat over the following two years, suggesting that water content could flag muscles at high risk of deterioration before the damage becomes irreversible.
18PubMed Central. Natural history of facioscapulohumeral muscular dystrophy evaluated by multiparametric quantitative MRIOn the blood-based side, two promising biomarkers have emerged. A circulating transcriptomic biomarker built from PAX7 target genes, measurable in a standard blood draw, has been validated as a classifier of clinical severity across independent patient cohorts, with stronger performance in older patients.
19PubMed Central. The FSHD muscle–blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophyMeanwhile, a plasma protein called KHDC1L, which is regulated by DUX4, was recently found to be significantly elevated in FSHD patients compared to healthy controls, with average levels roughly six times higher in FSHD plasma. Because KHDC1L is a secreted protein directly downstream of DUX4, it has potential not just as a disease marker but as a pharmacodynamic readout, meaning it could show whether a drug is actually reducing DUX4 activity in real time.
20Human Molecular Genetics. Identification of KHDC1L, a DUX4-regulated protein, as a novel plasma biomarker in facioscapulohumeral muscular dystrophyOn the functional side, a sensor-based measurement of upper-extremity reach called the Reachable Workspace has been validated for reliability and is being incorporated into trials as a way to capture shoulder and arm function, which standard walking tests miss entirely.
21PubMed. Reliability and Validity of the Reachable Workspace Total Score With Wrist Weight in Facioscapulohumeral Muscular DystrophyFaster and More Accurate Genetic Diagnosis
For decades, diagnosing FSHD genetically has required a laborious technique called Southern blot analysis, which involves physically sizing the D4Z4 repeat array using restriction enzymes and gel electrophoresis. The process is slow, demands large amounts of high-quality DNA, and is offered by only a handful of specialized laboratories. A newer technology called optical genome mapping is now being validated as an alternative.
Optical genome mapping works by imaging long strands of DNA labeled at specific sequence motifs, allowing direct visualization and sizing of the D4Z4 repeat array without the need for Southern blotting. In validation studies, it correctly confirmed FSHD1 in all cases previously diagnosed by Southern blot, with repeat sizing that matched within one unit, and it also successfully identified mosaic cases where only a fraction of a patient’s cells carry the contraction.
22PubMed Central. Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular DystrophyCombining optical genome mapping for the repeat array with standard next-generation sequencing for SMCHD1 variants offers a practical route to diagnosing both FSHD1 and FSHD2 with a single workflow that is faster and more accessible than current methods.
23PubMed Central. Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy in Patients Clinically Suspected of FSHD Using Optical Genome MappingIndependent clinical implementation has confirmed that the workflow is simpler and less time-consuming than Southern blot, and it has picked up de novo mosaic cases that traditional testing might miss or struggle to characterize.
24PubMed Central. Clinical Application of Optical Genome Mapping for Molecular Diagnosis of Facioscapulohumeral Muscular DystrophyExercise, Pain, and Day-to-Day Management
While the field waits for disease-modifying therapies, research on symptom management has quietly produced useful findings. A six-month randomized trial of home-based combined strength and aerobic training in FSHD patients found that the program improved aerobic fitness, muscle strength and endurance, walking speed, and reduced self-reported fatigue, without evidence of harm.
25PubMed Central. Safety and efficacy of a 6-month home-based exercise program in patients with facioscapulohumeral muscular dystrophyA separate rehabilitation program focusing on cardiorespiratory fitness and knee muscle strength found large improvements in walking speed and meaningful gains in knee flexor strength, along with reductions in fatigue and insomnia.
26International Journal of Rehabilitation Research. Fitness and walking outcomes following aerobic and lower extremity strength training in facioscapulohumeral dystrophyChronic pain is underappreciated in FSHD. In a survey of over 360 people with the disease, more than half reported chronic pain, with roughly a third of those describing it as severe. The most common site was the shoulder, and women reported pain more frequently than men.
27PubMed Central. Pain and QoL in FSHDA separate study found that over 80 percent of FSHD respondents experienced pain, with the lower back and legs as the most commonly affected areas. People with greater mobility limitations and those using assistive devices reported more severe pain, and the treatments patients found most helpful were not necessarily the ones most commonly prescribed.
28PubMed Central. Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophyBuilding the Infrastructure for Larger Trials
Running a clinical trial in a rare disease is inherently difficult. Patient populations are small, geographically scattered, and highly variable in how the disease presents. Several large-scale efforts are now working to address these barriers. The ReSolve study, a multi-center prospective study across eight US sites and three European sites, enrolled 220 genetically confirmed participants to validate new clinical outcome measures and refine trial design strategies over 18 months of longitudinal follow-up.
29PubMed Central. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve)National registries are also being strengthened. The Italian National Registry for FSHD, for instance, has implemented an enhanced data integration framework to systematically collect standardized clinical data, with the goal of enabling better natural history analysis and making it easier to identify and recruit suitable trial candidates.
30PubMed Central. The Italian National Registry for FSHDExtramuscular Symptoms and Early-Onset Disease
FSHD is primarily known as a muscle disease, but it can affect other organ systems, particularly in patients with early-onset forms. Hearing and vision problems have been reported in a sizable proportion of patients and tend to be more pronounced in those whose symptoms began before age 10. A case study of a 10-year-old boy with FSHD documented severe bilateral sensorineural hearing loss, which contributed to speech delays compounded by facial muscle weakness.
31Dove Press. Hearing, Voice and Speech Disorders in 10-Year-Old-Boy with Facio-Scapulo-Humeral Dystrophy (FSHD) – Case StudyThese extramuscular features deserve more attention from clinicians, especially in pediatric patients. Hearing screenings, in particular, could catch impairments early enough to intervene with hearing aids or speech therapy before they compound the functional challenges already imposed by muscle weakness. As research attention broadens beyond the core muscle pathology, understanding and managing these additional disease features will become an increasingly important part of FSHD care.